 |
Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) is the only triple-action cream for the short-term and intermittent long-term treatment of moderate to severe melasma of the face. To see a prominent dermatologist explain how to use Tri-Luma® Cream, watch this video  .
Tri-Luma® Cream can help reduce or eliminate the discoloration caused by melasma. In fact, the combination of the three active ingredients in Tri-Luma® Cream is more effective than any combination of the individual components. Women treated with
Tri-Luma® Cream also reported a favorable side effect profile as compared to women using various combinations of the ingredients.² Up close and personal: See one woman's story.
To see how melasma occurs and how Tri-Luma® Cream can reduce the discoloration, watch this animation.
|
After using Tri-Luma® Cream for 8 weeks — women embarrassed to some degree by their melasma dropped from 82% of respondents to 40%.¹ |
Tri-Luma® Cream has been clinically proven — in three studies — to improve and frequently clear melasma after eight weeks of treatment. If melasma has not cleared in eight weeks, the latest long-term safety studies confirm that Tri-Luma® Cream is safe to use until melasma is resolved. It is also safe to use again whenever the condition reappears. Because melasma can be worsened by sun exposure, long-term therapy should include sun protection.
Women who are pregnant, plan to become pregnant or are nursing should wait to begin treatment with Tri-Luma® Cream until after pregnancy or when nursing has concluded. The safety and efficacy of Tri-Luma® Cream in pregnant women and nursing mothers have not been established.
Do you know someone with melasma?
If you think you know someone who may have melasma, share the information you've learned with them by emailing this page to your friend. |
Please see full prescribing information.
1. Grimes P. Incidence and psychosocial implications of melasma. Presented at: American Academy of Dermatology; July 25-29, 2003; Chicago, Ill.
2. Data on file, Galderma Laboratories, L.P.
Tri-Luma® Cream is contraindicated in individuals with a hypersensitivity, allergy or intolerance to fluocinolone acetonide, hydroquinone or tretinoin. In clinical trials, the most frequently reported side effects were erythema, desquamation, burning, dryness and pruritus.
Mild to moderate redness, peeling, burning, dryness or itching may be experienced. This product contains sulfites that may cause severe allergic reactions including anaphylactic symptoms and life-threatening asthma attacks. Exposure to sunlight, sunlamps or UV light and extreme heat, wind or cold should be avoided. Use of sunscreen with appropriate SPF of 30 or higher is required. Wear protective clothing and change to nonhormonal forms of birth control, if hormonal methods are used.
Tri-Luma® Cream contains hydroquinone, which may produce exogenous ochronosis, a gradual blue-black darkening of the skin, whose occurrence should prompt discontinuation of therapy. Tri-Luma® Cream contains the corticosteroid fluocinolone acetonide. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment.
|
